The previous page is sending you to https://www.forbes.com/sites/joshuacohen/2023/06/02/coherus-biosciences-and-mark-cubans-drug-company-aim-to-disrupt-humira-referenced-biosimilar-space-with-launch-of-yusimry-at-a-85-discount/.

 If you do not want to visit that page, you can return to the previous page.